Association Between Cancer and Anti-synthetase Syndrome

• Conditions: Antisynthetase Syndrome

• Registration Number: NCT04941547
• Lead Sponsor: Central Hospital, Nancy, France

Brief Summary

Among Idiopathic inflammatory myopathies, antisynthetase syndrome is meant to be rarely associated with cancer. However, clinical evidences of the association of those diseases led to the hypothesis that previous studies might have underestimated the prevalence of cancer in patients with antisynthetase syndrome. The aim of this study was to assess the prevalence of cancer in patients with antisynthetases syndrome in Grand Est and Bourgogne Franche-Comté regions.

Detailed Description

Idiopathic inflammatory myopathies area heterogeneous group of disease involving mainly muscles, which paraneoplastic feature has been well characterized, specifically in some subgroups such as dermatomyositis. In contrast, antisynthetase syndrome is thought to be rarely associated with cancer. However, clinical observations of the association of those diseases led us to the hypothesis that previous studies might have underestimated the prevalence of cancer in patients with antisynthetase syndrome. The aim of this study was to assess the prevalence of cancer in patients with antisynthetases syndrome in Grand Est and Bourgogne Franche-Comté regions, describing the type of cancer observed as well as clinical features of patients and diagnostic work-up leading to the diagnosis of cancer.

Study Timeline

• Study Start: 2021-04-01
• Status Verified: 2021-05
• Study First Submitted: 2021-06-22
• Study First Submitted QC: 2021-06-22
• Last Update Submitted: 2021-06-22
• Study First Posted: 2021-06-28
• Last Update Posted: 2021-06-28
• Primary Completion: 2021-07-31
• Study Completion: 2021-09-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• adult patients
• positive antisynthetase antibodies (JO-1,PL12, PL17, EJ, OJ, KS, RS, YRS)

Exclusion Criteria

• age under 18
• opposition to data collection
• no positive antisynthetase antibodies
• absence of clinical involvment

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
cancer prevalence	baseline	prevalence of cancer among patients with antisynthetase syndrome

Secondary Outcome Measures

Name	Time	Method
description of cancer type in patients with antisynthetase syndrome	baseline	description of the type and stage of cancer in patients with antisynthetase syndrome
factors associated with cancer	baseline	comparison of clinical and paraclinical features associated with cancer in patients with antisynthetase syndrome

Trial Locations

Locations (1)

Thomas Moulinet; 🇫🇷 Vandoeuvre les nancy, Lorraine, France